Enhancing patient safety: leveraging artificial intelligence-powered electronic medical records for effective drug-drug interaction nudge in real-world prescribing practices

Authors

  • G. Jayanthy Department of Clinical Insights, HealthPlix Technologies, Bengaluru, Karnataka, India
  • Arnab Majumdar Department of Clinical Insights, HealthPlix Technologies, Bengaluru, Karnataka, India
  • Supriya Kaloo Department of Clinical Insights, HealthPlix Technologies, Bengaluru, Karnataka, India
  • Snehal Shah Department of Clinical Insights, HealthPlix Technologies, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20241653

Keywords:

HealthPlix EMR, Drug-drug interactions, Nudges, Real-world

Abstract

Background: Concurrent prescriptions of various medications may lead to unfavorable and unanticipated potential drug-drug interactions. Hence, the elimination of drug-drug interactions is a key aspect of delivering a coherent treatment regime. In response to this concern, HealthPlix, one of India's largest AI-powered electronic medical record providers, introduced a drug-drug interaction nudge feature in June 2022, providing a proactive solution for physicians to address potential interactions between incompatible drugs. This study aimed to elucidate the role of electronic medical records in identifying and managing drug interactions and the advantages of interaction nudges for doctors in prescribing appropriate medications.

Methods: An observational retrospective study was conducted using data obtained from HealthPlix, containing two or more drugs, written for patients older than 18 years.

Results: In an average of 1.9 million patient visits analyzed, the interaction visits were observed to be 1.2 million. An average of 185,745 interactions were observed during the study period. For all observed interactions, an average of 72,383 molecules were removed. These results provide insights into the efficiency of HealthPlix in abrogating interactions and illustrate the tangible benefits of nudges in modifying prescription practices.

Conclusions: The above results illustrate the effectiveness of drug-drug interaction nudges as a clinical decision support tool integrated into HealthPlix, marking a significant advancement in Indian healthcare. This unique feature contributes to reducing the frequency of potent drug interactions, showcasing its potential to enhance patient safety and improve the quality of healthcare delivery.

References

Kardas P, Urbański F, Lichwierowicz A, Chudzyńska E, Czech M, Makowska K, et al. The prevalence of selected potential drug-drug interactions of analgesic drugs and possible methods of preventing them: lessons learned from the analysis of the real-world national database of 38 million citizens of Poland. Front Pharmacol. 2021;11:607852.

Mino-León D, Galván-Plata ME, Doubova SV, Flores-Hernández S, Reyes-Morales H. A pharmacoepidemiological study of potential drug interactions and their determinant factors in hospitalized patients. Rev Invest Clin. 2011;63:170-8.

Strandell J, Bate A, Lindquist M, Edwards IR. Drug-drug interactions-a preventable patient safety issue? Br J Clin Pharmacol. 2008;65(1):144-6.

Medina-Barajas F, Vázquez-Méndez E, Pérez-Guerrero EE, Sánchez-López VA, Hernández-Cañaveral II, Gabriel ARO, et al. Pilot study: evaluation of potential drug-drug interactions in hospitalized pediatric patients. Pediatr Neonatol. 2020;61(3):279-89.

Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin. Pharmacokinet. 2010;49:509-33.

Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18:601-10.

Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45:301-8.

Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935-41.

Abdulah R, Suwandiman TF, Handayani N, Destiani DP, Suwantika AA, Barliana MI, et al. Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. Ther Clin Risk Manag. 2017;13:919-25.

Bethi Y, Shewade DG, Dutta TK, Gitanjali B. Prevalence and predictors of potential drug-drug interactions in patients of internal medicine wards of a tertiary care hospital in India. Eur J Hosp Pharm. 2018;25:317-21.

Daggupati SJV, Saxena PUP, Kamath A, Chowta MN. Drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention. Int J Clin Pharm. 2020;42(1):132-40.

Očovská Z, Maříková M, Vlček J. Potentially clinically significant drug-drug interactions in older patients admitted to the hospital: a cross-sectional study. Front Pharmacol. 2023;14:1088900.

Santibáñez C, Roque J, Morales G, Corrales R. Characteristics of drug interactions in a pediatric intensive care unit. Rev Chil Pediatr. 2014;85:546-53.

van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22:2334-41.

van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108:1071-8.

Diksis N, Melaku T, Assefa D, Tesfaye A. Potential drug-drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia. SAGE Open Med. 2019;7:2050312119857353.

Mousavi S, Ghanbari G. Potential drug-drug interactions among hospitalized patients in a developing country. Caspian J Intern Med. 2017;8(4):282-8.

Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251-63.

Abbas S, Ihle P, Harder S, Schubert I. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf. 2015;24(4):406-13.

Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550-4.

Tao D, Wang H, Xia F, Ma W. Pancytopenia due to possible drug-drug interactions between low-dose methotrexate and proton pump inhibitors. Drug Healthc Patient Saf. 2022;14:75-8.

Rawal KB, Mateti UV, Shetty V, Shastry CS, Unnikrishnan MK, Shetty S, et al. Development of evidence-based indicators for the detection of drug-related problems among ovarian cancer patients. Front Pharmacol. 2023;14:1203648.

Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med. 2010;268(4):359-66.

Bleakley S. Antidepressant drug interactions: evidence and clinical significance. Prog Neuro Psych. 2016;21-7.

Downloads

Published

2024-06-25

How to Cite

Jayanthy, G., Majumdar, A., Kaloo, S., & Shah, S. (2024). Enhancing patient safety: leveraging artificial intelligence-powered electronic medical records for effective drug-drug interaction nudge in real-world prescribing practices. International Journal of Basic & Clinical Pharmacology, 13(4), 520–525. https://doi.org/10.18203/2319-2003.ijbcp20241653

Issue

Section

Original Research Articles